GlassScriptPhysician profile
Anish S Konde
NPI 1417343971
$7,936.89
in general payments reported to CMS, 2019-2025
22 companies · $2,343 in 2025
The $2,343 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $954 · 2020: $97.81 · 2021: $51.21 · 2023: $2,140 · 2024: $2,351 · 2025: $2,343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,215 · Food and Beverage: $419 · Honoraria: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,215.00 |
| Food and Beverage | $418.99 |
| Honoraria | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,962.47 | 2019-2025 | Imfinzi, Truqap, Calquence |
| Daiichi Sankyo INC. | $2,800.90 | 2023-2025 | Vanflyta, Enhertu |
| Beigene USA, INC. | $675.00 | 2024 | Brukinsa |
| Amgen INC. | $287.43 | 2019 | |
| Exelixis INC. | $171.04 | 2019-2021 | |
| Boston Scientific Corporation | $141.57 | 2025 | Exalt Model D |
| Kite Pharma, INC. | $133.36 | 2019 | |
| Caris Mpi, INC. | $129.85 | 2025 | Mi Cancer Seek |
| Incyte Corporation | $124.99 | 2019 | |
| Agios Pharmaceuticals, INC. | $120.60 | 2019 | |
| Janssen Biotech, INC. | $100.59 | 2024 | Rybrevant |
| Dova Pharmaceuticals | $86.55 | 2020 | |
| Tersera Therapeutics LLC | $38.27 | 2019 | |
| Abbvie INC. | $36.08 | 2025 | |
| Novartis Pharmaceuticals Corporation | $27.14 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $19.89 | 2019 | |
| Tesaro, INC. | $18.23 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.69 | 2019 | |
| Genzyme Corporation | $13.50 | 2019 | |
| Clovis Oncology, INC. | $12.11 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.37 | 2019 | |
| Array Biopharma INC | $11.26 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anish Konde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.